Matica Biotechnology, the U.S. subsidiary of CHA Biotech (085660.KQ), will provide process optimization services to Bondwell Technologies of the U.S. for the production of next-generation protein materials.
Matica Bio said on the 21st that it is partnering with Bondwell to develop manufacturing processes for next-generation protein materials. Drawing on the process development expertise it has built in cell and gene therapy (CGT), the company plans to accelerate the timeline for producing the protein materials Bondwell is developing and to support their commercialization.
Bondwell develops next-generation protein technologies for use in advanced life sciences. The company is building a proprietary protein biomaterials platform that harnesses the binding and self-assembly properties proteins display in nature. It aims to apply the platform to pharmaceuticals, environmental applications and energy.
Matica Bio plans to use the partnership as a springboard to expand business with research institutions and biotech companies in Texas. College Station, Texas, where Matica Bio is based, hosts a cluster of biotech firms and research laboratories centered on Texas A&M University. Matica Bio intends to work with companies and laboratories that have yet to establish manufacturing processes, engaging them from the earliest stages of development to secure them as clients ahead of rivals.
"As Texas establishes itself as a hub of biotech innovation, cooperation among local companies is becoming more important," Matica Bio CEO Paul Kim said. "We will work with biotech companies in Texas to nurture innovative technologies and strengthen the competitiveness of the region's biotech ecosystem."
Matica Bio was set up by CHA Biotech to enter the U.S. market for CGT contract development and manufacturing (CDMO). In 2022 it completed a CGT CDMO facility in College Station, Texas — the only such plant built by a Korean company. It is expanding orders on the strength of its proprietary cell line MatiMax™ and its analytical development and process development capabilities.
